| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| NRX Pharmaceuticals Inc. | Remdesivir and ZYESAMI (Aviptadil) - (ACTIV-3b NIH trial) | COVID-19 | Phase 3 | Trial Discontinued | Intravenous | COVID-19 |
| NRX Pharmaceuticals Inc. | BriLife | Covid-19 Variants of Concern Vaccine | Phase 2/3 | Trial Discontinued | Intramuscular | COVID-19 |
| NRX Pharmaceuticals Inc. | BriLife002 | COVID-19 Vaccine | Phase 2/3 | Trial Discontinued | Intramuscular | COVID-19 |
| NRX Pharmaceuticals Inc. | BriLife | COVID-19 vaccine | Phase 2/3 | Trial Discontinued | Intramuscular | COVID-19 |
| NRX Pharmaceuticals Inc. | NRX-101 | Bipolar Depression in patients with Acute suicidal ideation | Phase 2/3 | Enrollment Conclusion | Oral | Psychiatric |
| NRX Pharmaceuticals Inc. | Intravenous ZYESAMI (Aviptadil) | COVID-19 | Phase 2/3 | Trial Discontinued | Intravenous | COVID-19 |
| NRX Pharmaceuticals Inc. | NRX-101 | Bipolar depression w/ Sub-Acute Suicidal Ideation & Behavior (SSIB) | Phase 2 | Ongoing | Oral | Psychiatric |
| NRX Pharmaceuticals Inc. | nebulized ZYESAMI (Aviptadil) - (I-SPY COVID) | COVID-19 | Phase 2 | Trial Discontinued | Inhalation | COVID-19 |